CD301b+ monocyte-derived dendritic cells mediate resistance to radiotherapy
Sirimuvva Tadepalli, Derek R. Clements, Hayley M. Raquer-McKay, Anja Lüdtke, Sanjana Saravanan, David Seong, Lorraine Vitek, Christopher M. Richards, Jan E. Carette, Matthias Mack, Andres Gottfried‐Blackmore, Edward E. Graves, Juliana Idoyaga
Abstract
Monocytes infiltrating tumors acquire various states that distinctly impact cancer treatment. Here, we show that resistance of tumors to radiotherapy (RT) is controlled by the accumulation of monocyte-derived dendritic cells (moDCs). These moDCs are characterized by the expression of CD301b and have a superior capacity to generate regulatory T cells (Tregs). Accordingly, moDC depletion limits Treg generation and improves the therapeutic outcome of RT. Mechanistically, we demonstrate that granulocyte-macrophage colony-stimulating factor (GM-CSF) derived from radioresistant tumor cells following RT is necessary for the accumulation of moDCs. Our results unravel the immunosuppressive function of moDCs and identify GM-CSF as an immunotherapeutic target during RT.